BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab
June 17, 2019 07:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, June 17, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
Hagens Berman Sobol Shapiro LLP Logo
Hagens Berman Alerts Investors in Celgene Corporation to the Expanded Class Period and Reminds Them of the May 29, 2018 Securities Class Action Lead Plaintiff Deadline
May 04, 2018 17:53 ET | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, May 04, 2018 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in Celgene Corporation (NASDAQ:CELG) of the May 29, 2018 Lead Plaintiff deadline.  If you purchased...
Hagens Berman Sobol Shapiro LLP Logo
Hagens Berman Alerts Investors in Celgene Corporation to the May 29, 2018 Lead Plaintiff Deadline in the Pending Securities Class Action and to the Abrupt Departure of Celgene’s President
April 06, 2018 16:30 ET | Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, April 06, 2018 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in Celgene Corporation (NASDAQ:CELG) to the May 29, 2018 Lead Plaintiff deadline in the securities...
Celgene May Also Want to Take Notice of PharmaCyte Biotech
July 24, 2015 09:00 ET | PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - July 24, 2015) - A recent deal between Celgene and Juno Therapeutics is just a microcosm of the mindset that may ultimately drive a similar deal between it -- or a...
Nuvilex Inc., TD2 and the PCRT Should Draw Great Interest to the Company's Pancreatic Cancer Treatment
June 20, 2014 09:00 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 20, 2014) - Nuvilex, Inc. (OTCQB: NVLX) can accomplish more in its upcoming preclinical trials than many may realize. With the announcement that Translational...
Nuvilex CEO and COO Discuss Preclinical and Clinical Trials, Orphan Drug Status, Funding and Much More in Interview
June 04, 2014 08:30 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 4, 2014) - Nuvilex, Inc. (OTCQB: NVLX) President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company's...
Nuvilex Eyes FDA Accelerated Approval Process by Improving Quality of Life in Pancreatic Cancer Patients
May 23, 2014 09:00 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 23, 2014) - Nuvilex (OTCQB: NVLX) is calling it a "two pronged attack" on pancreatic cancer, but investors may be calling it an "end-around" or another avenue of...
Nuvilex Positioned for Lucrative Deal With Cell-in-a-Box Technology's Diverse Treatments Amid Biotech Frenzy
May 20, 2014 09:00 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 20, 2014) - Nuvilex, Inc. (OTCQB: NVLX) is up to much more than most are currently aware of, and it only takes a bit of digging to realize it. The company is clearly...
Nuvilex, Inc. Applying for Orphan Drug Status to Market Pancreatic Cancer Treatment Without Competition
April 22, 2014 08:45 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Apr 22, 2014) - When Nuvilex, Inc. (OTCQB: NVLX) named Clinical Network Services (CNS) as the Contract Research Organization (CRO) for its late phase clinical trials in...
Nuvilex, Inc. Could Obtain FDA Accelerated Approval After Phase 2b Clinical Trial
April 17, 2014 08:45 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Apr 17, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has once again delivered a major announcement as it advances its pancreatic cancer treatment toward late phase clinical...